HOME >> BIOLOGY >> NEWS
Institute for OneWorld Health CEO advocates focus first on developing world markets

Berkeley, Calif. May 11, 2004 New biotech processes are poised to change the economics of manufacturing drugs, creating the potential for delivering both affordable medicines to patients in the developing world and laying the foundation for new markets, according to Victoria Hale, Ph.D., CEO of the Institute for OneWorld Health. The founder of the first nonprofit pharmaceutical company in the U.S. spoke yesterday on a panel, "Synthetic Biology at the Edge" at the 8th International Biotech Summit in Berkeley.

Dr. Hale explained that diseases such as malaria and diarrhea, which are endemic in the developing world, afflict hundreds of millions of people, but affordable medicines are a major barrier to treatment. With advances in biotechnology, industry could achieve humanitarian goals and contribute to strengthening economies that ultimately benefit everyone.

As a step in that direction, malaria medicines will be among the first drugs to be manufactured through an innovative process developed by fellow panelist Jay D. Keasling, Ph.D., Professor of Chemical Engineering at the University of California, Berkeley. Dr. Keasling's team engineered a biotechnology process to make artemisinin, an anti-malarial compound. It is simpler and less expensive than today's laborious plant harvesting processes. This biotech process could be applied to several other kinds of pharmaceutical compounds which are otherwise expensive to synthesize or costly to extract from natural sources.

"By focusing first on the developing world, especially children, a healthier generation leads to greater prosperity, less dependence on foreign aid, and ultimately, creates new markets," Dr. Hale said. "The dynamics for significant change are underway for the private and public sectors, and business community to achieve mutually inclusive goals. We can all participant in and benefit from addressing global health inequities."

The World Health Organization recommends t
'"/>

Contact: Joanne Hasegawa
jhasegawa@oneworldhealth.org
415-421-4700
Institute for OneWorld Health
11-May-2004


Page: 1 2

Related biology news :

1. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
2. Schepens Eye Research Institute receives Roadmap grant to develop center for curing eye diseases
3. The future of HIV therapeutics is brightening, according to Gladstone Institutes Director
4. Institute for OneWorld Health nominated for the 2004 World Technology Awards
5. UNC researchers awarded $8.65 million from National Institute on Aging
6. Institute for OneWorld Health receives Gates Foundation grant
7. Lupus Research Institute awards $3 million in novel research grants to further new science in lupus
8. Virginia Bioinformatics Institute researcher advances fight against sudden oak death disease
9. Institute for OneWorld Health CEO to speak at BIO on leveraging opportunities for global health
10. Institute for Systems Biology, Pacific Northwest National Laboratory announce collaboration
11. Harvard Stem Cell Institute hosts inaugural symposia

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/12/2020)... SOUTHFIELD, Mich. (PRWEB) , ... August 11, 2020 ... ... Janssen R&D subsidiary based in Princeton, NJ, have entered into license agreements with ... discovery and development. Both Roche and J&J have annual Research and Development ...
(Date:8/7/2020)... ... 2020 , ... Alucio™, a fast-growing provider of cloud-based software ... Jessica Wong have joined the company’s leadership team as Vice President of Engineering, ... development efforts for Alucio’s flagship product, Beacon, an innovative cloud-based content management and ...
(Date:8/5/2020)... , ... August 05, 2020 , ... Regenative Labs has ... new innovations, CoreText™ and ProText™, making them the first Wharton’s jelly allografts to be ... a syringe. The company’s solutions are the first Wharton’s jelly allograft product to be ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... ... July 09, 2020 , ... ... of Technology (MIT) has expanded the company’s exclusive license to include clinical ... the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ ...
(Date:7/7/2020)... (PRWEB) , ... July 06, 2020 , ... R3 International ... program featuring up to 200 million stem cells. Depending on the patient's condition, treatment ... in the US will die having some form of Alzheimers dementia, and the incidence ...
(Date:7/1/2020)... ... June 29, 2020 , ... ... competitively procured purchasing contracts to its membership, recently named BioFit Engineered Products ... with the opportunity to purchase ergonomic seating, cafeteria tables, book trucks and carts ...
(Date:6/28/2020)... ... June 25, 2020 , ... With the COVID-19 pandemic ... drug treatment. In an effort to better understand the cellular responses to COVID-19, ... imaging dataset portraying therapeutic compound effects from over 1,600 approved and referenced molecules ...
Breaking Biology Technology:
Cached News: